Nitromed (MM) (NTMD) Quote

Still looking good...eom

On December 23, 2008, Archemix Corp. ("Archemix") , which is a party to that certain agreement and plan of merger dated November 18, 2008 by and between Archemix, NitroMed, Inc. ("NitroMed"), and Newport Acquisition Corp., a wholly owned subsidiary of NitroMed, issued a press release announcing a strategic alliance with GlaxoSmithKline. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with Archemix's proposed merger with NitroMed, Inc. ("NitroMed"), NitroMed has filed with the SEC a Registration Statement on Form S-4 containing a joint proxy statement/prospectus. Once the Form S-4 is declared effective by the SEC, the joint proxy statement/prospectus will be mailed to stockholders of NitroMed and Archemix. The joint proxy statement/prospectus will contain important information about NitroMed, Archemix, the transaction and related matters. In addition, NitroMed has filed with the SEC and mailed to its stockholders a definitive proxy statement in connection with the proposed sale of its BiDil? and BiDil XR? drug business to JHP Pharmaceuticals, LLC. The definitive proxy statement contains important information about NitroMed, the proposed sale of the BiDil and BiDil XR drug business and related matters. Investors and security holders of NitroMed and Archemix are urged to read carefully both the definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus relating to the merger (when it is available).
Investors and security holders of NitroMed are able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available), and other documents filed with the SEC by NitroMed through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders of NitroMed are able to obtain free copies of the definitive proxy statement for the proposed sale of the BiDil and BiDil XR drug business and the joint proxy statement/prospectus for the proposed merger (when it is available) by contacting NitroMed, Inc., Attn: Secretary, 45 Hayden Avenue, Suite 3000, Lexington, MA 02421. Investors and security holders of Archemix will be able to obtain free copies of the joint proxy statement/prospectus for the merger (when it is available) by contacting Archemix Corp., Attn: Secretary, 300 Third Street, Cambridge, MA 02142.
NitroMed, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the purchase and sale agreement with JHP Pharmaceuticals relating to the sale of the BiDil and BiDil XR drug business, and NitroMed and Archemix, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement with Archemix. Information regarding NitroMed's directors and executive officers is contained in NitroMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its proxy statement dated April 16, 2008, which are filed with the SEC, and in NitroMed's definitive proxy statement relating to the proposed sale of the BiDil and BiDil XR drug business, which was filed with the SEC on December 15, 2008. As of November 30, 2008, NitroMed's directors and executive officers, and funds affiliated with such individuals, owned approximately 33% of NitroMed's common stock. A more complete description of the interests of NitroMed's directors and officers is available in the definitive proxy statement relating to the sale of the BiDil and BiDil XR drug business. In addition, information regarding Archemix's

So now NTMD get "as much as $1.4 billion". so if they get 30%, that gives NTMD a possible a 420 million stake in this merger.

http://biz.yahoo.com/ap/081223/eu_britain_glaxosmithkline.html?.v=8

TOLD YA!!!!...eom

Looking ready...eom

Watching this...eom

NTMD - NitroMed, Inc. T3
HALT Date: 11/18/2008
HALT Time: 16:28:41

RESUME DATE: 11/18/2008
QUOTE RESUME TIME: 16:55:00
ANTICIPATED TRADE RESUME TIME: 17:00:00


NASDAQ MarketWatch has issued the above trading status change(s). NASDAQ
issues may be subject to a one minute extension due to a Liquidity
Imbalance before trading resumes. Further detail on current and recent
trade halt activity is available on NASDAQTrader.com by clicking on the
link above. Questions regarding trading halts can be directed to
MarketWatch at (800) 537-3929 or (301) 978-8500

Not currently in NTMD, it may be worth a tax loss bounce play and the shorts(1.8 million short) could help if it ran. Longer term this one is going to zero or will have to merge with another company.

what's your opinion on this?

noticed it broke big trendline

wonder how far down it will go

NitroMed Reports Financial Results for Third Quarter 2007

Conference Call and Webcast Today at 8:30 AM EDT

NitroMed, Inc. (NASDAQ: NTMD), an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, today reported financial results for its third fiscal quarter and year to date ended September 30, 2007.

Total revenues for the three months ended September 30, 2007 were $3.8 million compared to $3.4 million for the same period in 2006, an increase of $0.4 million or 10%. For the nine months ended September 30, 2007, total revenues were $11.0 million, compared to $8.6 million for the same period during 2006, an increase of $2.4 million, or 28%. Sales of BiDil accounted for all revenues during both periods.

Total operating expenses for the three months ended September 30, 2007, excluding cost of product sales, were $11.9 million, compared to $19.1 million for the same period in 2006, a decrease of $7.2 million or 38%. For the nine months ended September 30, 2007, total operating expenses, excluding cost of product sales, were $34.5 million, compared to $68.0 million for same period during 2006, a decrease of $33.5 million or 49%.

The substantial year-over-year decreases in operating expenses are primarily the result of the Company’s restructuring actions in March and October of 2006, which reduced costs and employee headcount in the areas of research and discovery, and sales and marketing, respectively; and decreased advertising and medical affairs expenditures that had supported the commercial launch of BiDil in 2006.

The Company’s net loss for the quarter ended September 30, 2007 was $8.4 million or $0.18 per common share, compared to a net loss of $16.5 million or $0.45 per common share for the same quarter in 2006. For the nine months ended September 30, 2007, the Company’s net loss was $24.7 million or $0.60 per common share, compared to a net loss of $60.7 million or $1.68 per common share for the same period in 2006.

At September 30, 2007, the Company had cash, cash equivalents and marketable securities totaling $38.2 million, a decrease of $3.9 million from December 31, 2006. In May 2007, the Company raised net proceeds of $18.2 million in a registered direct offering of its common stock.

“During the third quarter, we succeeded in expanding the size of our field sales organization, as planned, with an experienced group of cardiovascular sales professionals,” said Kenneth M. Bate, NitroMed’s President and Chief Executive Officer. “We welcome these newest members of the BiDil team, who are focused on pull-through efforts at the local physician level. Broadly aiding our field efforts, in September we placed a series of nationwide BiDil advertisements in the leading cardiovascular journals. In addition, we launched an information-rich website, BiDil.com, that includes a BiDil sample-ordering option for physicians. These efforts, combined with affordable reimbursement for BiDil on a substantial majority of health care plans, provide strong impetus for building the BiDil market, and we look forward to monitoring their impact on fourth quarter sales.”

James G. Ham, III, NitroMed’s Chief Financial Officer, commented, "During the third quarter, we continued to aggressively manage our cash burn to a rate of $6.2 million, which was a slight decrease from second quarter burn. For the year 2007, we project operating expenses to be approximately $50 million, including share-based compensation expense related to SFAS 123R but excluding cost of product sales.”

Corporate Highlights

Accomplishments realized by NitroMed during the third quarter of 2007 include:

* The publication in the September issue of Clinical Pharmacokinetics, a peer-reviewed scientific journal, demonstrating that two different combinations of individual isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD), used in the Vasodilator-Heart Failure Trials (V-HeFT) I and II are not bioequivalent to BiDil, the fixed-dose combination of ISDN and HYD, used in the African American Heart Failure Trial (A-HeFT). The study compared identical amounts of the formulations of ISDN and HYD used in V-HeFT I and II, and BiDil, the proprietary fixed dose combination, used in A-HeFT and demonstrated that the formulations used in V-HeFT I and V-HeFT II are neither bioequivalent to each other, nor to BiDil. Generic formulations of ISDN and HYD have not been shown to be bioequivalent to BiDil and there is no basis to conclude that the clinical efficacy and outcomes results of generic ISDN and HYD will be the same as BiDil.
* The presentation in September of five abstracts at the 11th Annual Scientific Meeting of the Heart Failure Society of America. The new data broadens the clinical understanding of BiDil by adding to the body of evidence that BiDil represents important adjunct therapy in the treatment of black heart failure patients. The data presented regarding mortality in high risk heart failure patients with atrial fibrillation, BiDil’s use in the elderly and with concomitant therapies, and genetic results will help heart failure specialists deliver optimal care to their patients.

* Improvement in preferred reimbursement for BiDil and inclusion of BiDil on key hospital formularies. Preferred reimbursement denotes a preferential level of reimbursement at which patient co-pays range from approximately $15.00 to $30.00 per prescription.
* The doubling of the Company’s BiDil field organization through the deployment of approximately 30 additional professionals with extensive cardiovascular sales, marketing and/or management experience at the end of the third quarter.

* The introduction of new BiDil marketing support, including:

-- Advertising placement in key cardiovascular medical journals.
-- The launch of BiDil.com (www.bidil.com), an information rich resource for cardiovascular health professionals, physicians, and black heart failure patients.

Webcast and Conference Call

NitroMed will host a webcast and conference call, including an open question and answer session to discuss third quarter 2007 financial results and Company progress.
Date: Wednesday, October 31, 2007
Time: 8:30 a.m. Eastern Time
Access by Conference Call:
Domestic callers: Dial 800-299-8538
International callers: Dial 617-786-2902
Participant passcode: 40599135
Access by Webcast:
Go to www.nitromed.com for live webcast link.

An audio replay of the earnings conference call will be available two hours after the call and through November 7, 2007. The replay can be accessed by dialing 888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 56024019. The webcast will be archived on the Company’s website for an indefinite period of time following the earnings call.

About NitroMed, Inc.

NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company’s landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization.

For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc.

Forward Looking Statements

Statements in this press release about future expectations, plans and prospects for the Company, including the Company’s expectations regarding cash management and operating expenses in 2007, its positioning to achieve the Company’s goals and objectives in 2007, the expected benefit of its current sales organization expansion, its plans to build the market for the BiDil brand, the expected impact of such efforts in the fourth quarter of 2007 and beyond, and its plans to develop an extended release formulation of BiDil, known as BiDil XR™, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: difficulties in successfully developing, obtaining regulatory approval for, manufacturing and commercializing BiDil XR, including the Company’s ability to maintain third-party relationships for the development and manufacture of clinical and commercial quantities of BiDil XR on favorable terms, if at all; the Company’s ability to execute on its revised sales and marketing strategy for BiDil, including, without limitation, the Company’s ability to achieve anticipated cost reductions, the Company’s ability to successfully market and increase the sales of BiDil with limited sales force support and centralized marketing efforts, the Company’s ability to recruit the specialized sales representatives necessary to execute on this strategy, and the Company’s ability to successfully enter into a co-promotion agreement for BiDil on favorable terms, if at all; the Company’s ability to enter into collaboration or licensing arrangements with strategic partners related to its product candidate portfolio on favorable terms, if at all; the Company’s ability to obtain the substantial additional funding required to execute its business strategies; patient, physician and third-party payor acceptance of BiDil and/or BiDil XR, if successfully developed, as safe and effective therapeutics; the Company’s ability to obtain or maintain intellectual property protection and required licenses; unanticipated operating expenses for the remainder of fiscal year 2007 and beyond; and other important factors discussed in the Section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, which has been filed with the SEC, and in the other filings that the Company makes with the SEC from time to time. The forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Contact:

- Financial Tables Follow –
NITROMED, INC.
SELECTED FINANCIAL INFORMATION
(in thousands, except per share amounts)

CONDENSED STATEMENTS OF OPERATIONS
For the three and nine months ended September 30, 2007 and 2006
(Unaudited) Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Revenues:
Product revenue $ 3,759 $ 3,427 $ 11,042 $ 8,598

Cost and operating expenses:
Cost of product sales 560 1,310 2,151 2,827
Research and development 3,807 4,074 9,745 14,590
Sales, general and administrative 8,127 15,022 23,709 51,386
Restructuring charge - - 1,004 2,038

Total cost and operating expenses 12,494 20,406 36,609 70,841

Loss from operations (8,735 ) (16,979 ) (25,567 ) (62,243 )

Non-operating income, net 381 459 863 1,519

Net loss $ (8,354 ) $ (16,520 ) $ (24,704 ) $ (60,724 )

Basic and diluted net loss per common share $ (0.18 ) $ (0.45 ) $ (0.60 ) $ (1.68 )

Shares used in computing basic and diluted net loss per common share 45,180 37,090 40,877 36,146



CONDENSED BALANCE SHEETS
As of September 30, 2007 and December 31, 2006
(Unaudited)
September 30, December 31,
2007 2006
ASSETS

Cash and marketable securities $ 38,224 $ 42,153
Accounts receivable, net 1,515 1,370
Inventories 2,696 2,846
Other assets 1,072 2,336

Total assets $ 43,507 $ 48,705

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities $ 15,488 $ 15,898
Long-term debt - 3,728
Stockholders' equity 28,019 29,079

Total liabilities and stockholders' equity $ 43,507 $ 48,705

NitroMed, Inc.
Jane A. Kramer, 781.266.4220
C: 781.640.8499


Source: Business Wire (October 31, 2007 - 7:36 AM EDT)

News by QuoteMedia

Oversold with an Improving RSI (NTMD)

Bullish Hammer Patterns (NTMD)

Bullish Engulfing Patterns (NTMD)

Shame on the Congressional Black Caucus – Yes, This is About Biotech

Oct 1 2007
by Michael Shulman
BiotechBlitz

I live in Washington and there has been an almost unprecedented level of political scrutiny and interference with a Medicare decision to cut reimbursement guidelines for the anemia drug Aranesp when used in chemotherapy and renal dialysis. Hidden from the view of most people has been the role of the Congressional Black Caucus -- according to some analysts 40% or more of renal dialysis patients receiving Aranesp are African American.

So the lobbyists went to work, predicting dialysis treatment centers would close and African Americans would be hurt the most. One company operating centers, DaVita, which makes a profit on every does of Aranesp it administers spent $1.5 million bucks and Aranesp’s parent Amgen spent another half million dollars in the first half of this year.

I would love to know how much of that money went to Black Caucus members. And how much more since then. And when I have a bit of time, I will go through public records and find out.

Too bad these politicians and their staffers won’t work this hard for a critical life saving drug unless the company making that drug has the bucks to buy their time and attention. I am speaking of the drug BiDil from the company NitroMed (NTMD).

In clinical trials, BiDil reduced death from heart attacks by more than 40% in African Americans. Heck, the trial was stopped on ethical reasons so all the patients on placebo could switch to the medication -- it was so effective. It was approved by the FDA, the first drug every approved for use by one ethnic group. And Medicare, without any pressure from the Congressional Black Caucus that I could see, gave it a poor guideline for co-payment -- meaning it could cost users as much as $50 per month.

Given that BiDil should be taken with two other heart medications, a lot of people could not afford the co-pay and private insurers follow more often than not follow Medicare guidelines. The bottom line is hundreds, perhaps thousands of African Americans have needlessly died since the FDA approval -- needlessly because the drug is too expensive for too many people.

These unnecessary deaths FAR exceed the number of African Americans killed in Iraq. And guess who has made a major argument against the war? That most self-righteous group of politicians, the Congressional Black Caucus.

Their behavior is proof that racial politics has come mainstream. A political organizations supposedly organized to protect a certain group -- in this case African Americans -- really doesn’t give a damn about their constituents, unless they're lobbied (dare I say, paid) to do so.

BiDil(R) Gains Broad Preferred Status on Pharmacy Benefit Plans
Monday September 24, 8:30 am ET

LEXINGTON, Mass.--(BUSINESS WIRE)--NitroMed (NASDAQ: NTMD - News), said today that the reimbursement and formulary status of BiDil continues to improve. To date, approximately 80% of African Americans who have commercial and Medicare Part D and Medicaid prescription drug insurance coverage in the United States, have affordable access to BiDil. The company defines 'affordable' as Tier 2 status, meaning out-of-pocket co-payments for patients are approximately $25. BiDil®, the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD), is approved by the FDA as adjunct therapy in the treatment of heart failure in African Americans to improve survival, reduce hospitalization and improve patient functional status. Heart failure is a life threatening condition that disproportionately burdens African Americans.

"BiDil enjoys preferred formulary status on America's four largest Medicare Part D drug plans, and the two largest commercial drug plan providers," observed Gerald Bruce, NitroMed's Senior Vice President. "Additionally, BiDil is available at tier 2 through the two largest pharmacy benefit management formularies in the United States, and it is listed on the formularies of numerous hospitals that provide heart failure care to large numbers of African Americans. These strong coverage gains should once and for all put to rest the perception that BiDil is out of reach and costly. In fact, in many cases it is no more costly to patients than its untested component agents ISDN and HYD which the FDA has said are not bioequivalent to or substitutable for BiDil," he said. "Indeed, for the majority of patients, the out-pocket cost for evidence-based BiDil is less or comparable to the out-of-pocket cost of two prescription co-payments for the untested component agents."

The company said that the steady flow of clinical evidence supporting BiDil's efficacy, safety and its cost-effectiveness are factors in the strong contracting activity.

The company will issue a statement at 9:00 AM today regarding a published study on the use of BiDil's individual components that have not been shown to be bioequivalent to the fixed dose combination.

About NitroMed, Inc.

NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization.

For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc.

Improving Chaikin Money Flow (NTMD)

CCI Buy Signals (NTMD)

Three White Soldier Patterns (NTMD)
Bullish Reversal Patterns:

Parabolic SAR Buy Signals (NTMD) from nightly stockcharts.com scan

Oversold with an Improving RSI (NTMD) from nightly stockcharts.com scan

NitroMed Reports Financial Results for Second Fiscal Quarter 2007

Conference Call and Webcast to be Held Today at 8:00 AM ET

NitroMed, Inc. (NASDAQ: NTMD), an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, today reported financial results for its second fiscal quarter and year to date ended June 30, 2007.

Total revenues for the three months ended June 30, 2007 were $3.7 million compared to $2.9 million for the same period in 2006, an increase of $0.8 million, or 30%. For the six months ended June 30, 2007, total revenues were $7.3 million, compared to $5.2 million for the same period during 2006, an increase of $2.1 million, or 41%. Sales of BiDil accounted for all revenues during both periods.

Total operating expenses for the three months ended June 30, 2007, excluding cost of product sales, were $9.6 million, compared to $21.1 million for the same period in 2006, a decrease of $11.5 million or 55%. For the six months ended June 30, 2007, total operating expenses, excluding cost of product sales, were $22.5 million, compared to $48.9 million for same period during 2006, a decrease of $26.4 million or 54%.

The substantial year-over-year decreases in operating expenses are primarily the result of the Company’s restructuring actions in March and October of 2006, which reduced costs and employee headcount in the areas of research and discovery, and sales and marketing, respectively. Advertising and promotional expenses were also higher during the commercial launch phase for BiDil in 2006.

The Company’s net loss for the quarter ended June 30, 2007 was $6.2 million or $0.16 per common share, compared to a net loss of $18.3 million or $0.50 per common share for the same quarter in 2006. For the six months ended June 30, 2007, the Company’s net loss was $16.4 million or $0.42 per common share, compared to a net loss of $44.2 million or $1.24 per common share for the same period in 2006.

At June 30, 2007, the Company had cash, cash equivalents and marketable securities totaling $44.4 million, an increase of $2.3 million from December 31, 2006. In May 2007, the Company raised net proceeds of $18.3 million in a registered direct offering of its common stock.

Kenneth M. Bate, NitroMed’s President and Chief Executive Officer, stated, “During the quarter, we focused on expanding our U.S. field sales organization while continuing to achieve placements of BiDil on institutional formularies. We are also making good progress toward our goal of approximately doubling the size of our sales organization, with key managers now in place to direct a pull-through program for BiDil at the physician level. We feel confident that we are appropriately building the market for the BiDil brand, as we proceed with the development of an extended release formulation of BiDil.”

James G. Ham, III, NitroMed’s Chief Financial Officer, commented, "We’ve continued to carefully manage our expenses during the second quarter, and have again achieved a substantial reduction in sequential cash burn, which was $6.3 million during the second quarter of 2007. Our team and resources remain committed to the development of BiDil extended release and to supporting the currently marketed immediate release formulation of BiDil. For the year 2007, we are lowering our expense guidance, which we now project will be in the range of $50 - $55 million, including share-based compensation expense related to SFAS 123R but excluding cost of product sales.”

Corporate Highlights

Accomplishments realized by NitroMed during the second quarter of 2007 include:

* The publication in the June issue of the Journal of Cardiac Failure of remodeling data for BiDil. The article features outcomes for the African American Heart Failure Trial (A-HeFT), demonstrating further regression of left ventricular remodeling in an already well-treated black population with heart failure.
* The completion of a registered direct offering of the Company’s common stock in May 2007, resulting in net proceeds to the Company of $18.3 million.
* Improvement in preferred reimbursement for BiDil and inclusion of BiDil on key hospital formularies. Preferred reimbursement denotes a preferential level of reimbursement at which patient co-pays range from approximately $15.00 to $30.00 per prescription. The Company estimates that approximately 70% of African Americans with heart failure now have functional, affordable access to BiDil.

Webcast and Conference Call

NitroMed will host a webcast and conference call, including an open question and answer session to discuss second quarter 2007 financial results and Company progress.

Date: Wednesday, August 1, 2007
Time: 8:00 a.m. Eastern Time
Access by Conference Call:
Domestic callers: Dial 800-591-6944
International callers: Dial 617-614-4910
Participant passcode: 98059341
Access by Webcast:
Go to www.nitromed.com for live webcast link.

An audio replay of the earnings conference call will be available two hours after the call and through August 8, 2007. The replay can be accessed by dialing 888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 89122822. The webcast will be archived on the Company’s website for an indefinite period of time following the earnings call.

About NitroMed, Inc.

NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company’s landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization.

For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc.

Forward Looking Statements

Statements in this press release about future expectations, plans and prospects for the Company, including the Company’s expectations regarding cash management and operating expenses in 2007, its positioning to achieve the Company’s goals and objectives in 2007, its plans to expand its sales organization, its plans to build the market for the BiDil brand and its plans to develop an extended release formulation of BiDil, known as BiDil XR™, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: difficulties in successfully developing, obtaining regulatory approval for, manufacturing and commercializing BiDil XR, including the Company’s ability to maintain third-party relationships for the development and manufacture of clinical and commercial quantities of BiDil XR on favorable terms, if at all; the Company’s ability to execute on its revised sales and marketing strategy for BiDil, including, without limitation, the Company’s ability to achieve anticipated cost reductions, the Company’s ability to successfully market and increase the sales of BiDil with limited sales force support and centralized marketing efforts, the Company’s ability to recruit the specialized sales representatives necessary to execute on this strategy, and the Company’s ability to successfully enter into a co-promotion agreement for BiDil on favorable terms, if at all; the Company’s ability to enter into collaboration or licensing arrangements with strategic partners related to its product candidate portfolio on favorable terms, if at all; the Company’s ability to obtain the substantial additional funding required to execute its business strategies; patient, physician and third-party payor acceptance of BiDil and/or BiDil XR, if successfully developed, as safe and effective therapeutics; the Company’s ability to obtain or maintain intellectual property protection and required licenses; unanticipated operating expenses for the remainder of fiscal year 2007 and beyond; and other important factors discussed in the Section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, which has been filed with the SEC, and in the other filings that the Company makes with the SEC from time to time. The forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

NITROMED, INC.
SELECTED FINANCIAL INFORMATION
(in thousands, except per share amounts)


CONDENSED STATEMENTS OF OPERATIONS
For the three and six months ended June 30, 2007 and 2006

(Unaudited) Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
Revenues:
Product revenue $ 3,715 $ 2,855 $ 7,283 $ 5,171

Cost and operating expenses:
Cost of product sales 637 621 1,591 1,517
Research and development 2,931 4,516 5,938 10,515

Sales, general and administrative
6,634 16,580 15,582 36,365

Restructuring charge
- - 1,004 2,038

Total cost and operating expenses 10,202 21,717 24,115 50,435

Loss from operations (6,487 ) (18,862 ) (16,832 ) (45,264 )

Non-operating income, net 251 582 482 1,060

Net loss $ (6,236 ) $ (18,280 ) $ (16,350 ) $ (44,204 )

Basic and diluted net loss per common share $ (0.16 ) $ (0.50 ) $ (0.42 ) $ (1.24 )

Shares used in computing basic and diluted net loss per common share 40,100 36,724 38,689 35,667


CONDENSED BALANCE SHEETS
As of June 30, 2007 and December 31, 2006
(Unaudited)
June 30, December 31,
2007 2006
ASSETS

Cash and marketable securities $ 44,446 $ 42,153
Accounts receivable, net 1,368 1,370
Inventories 2,986 2,846
Other assets 1,214 2,336

Total assets $ 50,014 $ 48,705

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities $ 14,964 $ 15,692
Deferred revenue - 206
Long-term debt - 3,728
Stockholders' equity 35,050 29,079


Total liabilities and stockholders' equity
$ 50,014 $ 48,705

NitroMed, Inc.
Jane A. Kramer, 781-266-4220
C: 781-640-8499


Source: Business Wire (August 1, 2007 - 6:15 AM EST)

News by QuoteMedia
www.quotemedia.com

NitroMed Announces Sale of Common Stock

NitroMed, Inc. (NASDAQ:NTMD) announced today that it entered into definitive agreements to sell approximately 7.6 million shares of its common stock to selected institutional investors at a price of $2.60 per share. The shares were offered under NitroMed’s effective shelf registration statement previously filed with the Securities and Exchange Commission on August 3, 2005. Proceeds to NitroMed from this registered direct offering, net of offering expenses and placement agency fees, total approximately $18.3 million. The net proceeds of the financing are expected to be used for general corporate purposes, including sales, marketing and commercialization efforts for NitroMed’s product, BiDil® (isosorbide dinitrate/hydralazine hydrochloride), and the development of an extended release version of BiDil designed to be taken once per day, known as BiDil XR™.

Thomas Weisel Partners LLC acted as the sole placement agent in this offering. Copies of the final prospectus relating to this offering may be obtained from Thomas Weisel Partners LLC, One Montgomery Street, San Francisco, California 94104.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NitroMed, Inc.

NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company’s landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization.

For full prescribing information, visit: www.BiDil.com. BiDil® is a registered trademark of NitroMed, Inc.

Forward Looking Statements

Statements in this press release about future expectations, plans and prospects for the Company, including the Company’s expected use of the proceeds of its registered direct offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: difficulties in successfully developing, obtaining regulatory approval for, manufacturing and commercializing BiDil XR, including the Company’s ability to maintain third-party relationships for the development and manufacture of clinical and commercial quantities of BiDil XR on favorable terms, if at all; the Company’s ability to execute on its revised sales and marketing strategy for BiDil, including without limitation, the Company’s ability to achieve anticipated cost reductions, the Company’s ability to successfully market and increase the sales of BiDil with limited sales force support and centralized marketing efforts, the Company’s ability to recruit the specialized sales representatives necessary to execute on this strategy, and the Company’s ability to successfully enter into a co-promotion agreement for BiDil on favorable terms, if at all; the Company’s ability to enter into collaboration or licensing arrangements with strategic partners related to its product candidate portfolio on favorable terms, if at all; the Company’s ability to obtain the substantial additional funding required to execute its business strategies; patient, physician and third-party payer acceptance of BiDil and/or BiDil XR, if successfully developed. as safe and effective therapeutics; the Company’s ability to obtain or maintain intellectual property protection and required licenses; unanticipated operating expenses for the remainder of fiscal year 2007 and beyond; and other important factors discussed in the Section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, which has been filed with the SEC and in other filings the Company makes with the SEC from time to time. The forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

NitroMed, Inc.
Jane Kramer, 781-266-4220
C: 781-640-8499

Source: Business Wire (May 24, 2007 - 8:59 AM EDT)

Oversold with an Improving RSI (NTMD) from stockcharts.com nightly scan.